Andrew Blauvelt - Concepedia

Author

Andrew Blauvelt

Oregon Medical Research Center

Also Known As

Andrew Blauvelt

Publications

405

Citations

H-Index

Concepts

All Affiliations

Oregon Medical Research Center Probity Medical Research Icahn School of Medicine at Mount Sinai George Washington University University of Lübeck

About

Andrew Blauvelt is an author at Oregon Medical Research Center specializing in immunology, medicine, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	162
2	Public Health	1	1	80
3	Cell Biology	1	1	82
4	Cellular Physiology	1	1	82
5	Epidemiology	1	1	80

Andrew Blauvelt

Publications

338

Citations

H-Index

Page 1

	Year	Citations
Human Langerhans Cells Express E-Cadherin Andrew Blauvelt, Stephen I. Katz, Mark C. Udey Journal of Investigative Dermatology Cell InteractionCell TraffickingImmunologyCell-matrix InteractionCytoskeleton	1995	82
Human Herpesvirus 8 Infection Occurs following Adolescence in the United States Andrew Blauvelt, Shizuko Sei, Pamela Cook, The Journal of Infectious Diseases Diagnostic VirologyViral PersistenceVirus EpidemiologyAdolescent MedicineViral Diagnostics	1997	80
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up) Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati, Journal of the American Academy of Dermatology	2023	44
Long-term radiographic follow-up after isotretinoin therapy Charles N. Ellis, David R. Pennes, Richard C. Hermann, Journal of the American Academy of Dermatology Interventional RadiologyPharmacotherapyRadiologyIsotretinoin Therapy	1988	40
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial Andrew Blauvelt, Zoé Kececioglu Draelos, Linda Stein Gold, Journal of the American Academy of Dermatology	2024	37
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials Andrew Blauvelt, Mark Lebwohl, Richard G. Langley, Journal of the American Academy of Dermatology	2023	19
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis Andrew Blauvelt, Phoebe Rich, Howard Sofen, Journal of the American Academy of Dermatology	2023	19
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study Karen A. Veverka, Steven Tien Guan Thng, Jonathan I. Silverberg, Journal of the American Academy of Dermatology	2023	17

Page 1